REDWOOD CITY, Calif.,
Oct. 27, 2015 /PRNewswire/ -- Genomic
Health, Inc. (Nasdaq: GHDX) today announced that the company will
host a conference call and webcast on Tuesday, November 3 at 4:30 p.m. Eastern Time to discuss its third
quarter 2015 financial results. The call and webcast will follow
the release of the third quarter financial results after market
close.
Conference Call Details
To access the live conference call on November 3 at 4:30 p.m.
Eastern Time via phone, please dial (877) 303-7208 from
the United States and Canada, or +1 (224) 357-2389
internationally. The conference call ID is 54340252. Please
dial in approximately 10 minutes prior to the start of the
call.
To access the live and subsequently archived webcast of the
conference call, go to the Investor Relations section of
the company's web site at
http://investor.genomichealth.com. Please connect to the web
site at least 15 minutes prior to the call to allow for any
software download that may be necessary.
About Oncotype DX®
The Oncotype
DX® portfolio of breast, colon and prostate cancer tests
applies advanced genomic science to reveal the unique biology of a
tumor in order to optimize cancer treatment decisions. With half a
million patients tested in more than 90 countries, the Oncotype DX
tests have redefined personalized medicine by making genomics a
critical part of cancer diagnosis and treatment. To learn more
about OncotypeDX tests, visit: www.OncotypeDX.com,
www.mybreastcancertreatment.org and
www.myprostatecancertreatment.org.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider
of genomic-based diagnostic tests that address both the
overtreatment and optimal treatment of early-stage cancer, one of
the greatest issues in healthcare today. The company is applying
its world-class scientific and commercial expertise and
infrastructure to lead the translation of massive amounts of
genomic data into clinically-actionable results for treatment
planning throughout the cancer patient's journey, from diagnosis to
treatment selection and monitoring. The company is based
in Redwood City, California, with international
headquarters in Geneva, Switzerland. For more
information, please visit, www.GenomicHealth.com and
follow the company on Twitter: @GenomicHealth, Facebook,
YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the benefits of the test to
physicians, patients and payors. Forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially, and reported results should not be considered
as an indication of future performance. These risks and
uncertainties include, but are not limited to: the ability of test
results to change treatment decisions; the risks and uncertainties
associated with the regulation of the company's tests; the results
of clinical studies; the applicability of clinical study results to
actual outcomes; the risk that the company may not obtain or
maintain sufficient levels of reimbursement, domestically or
abroad, for its existing tests and any future tests it may develop;
the risks of competition; unanticipated costs or delays in research
and development efforts; and the other risks set forth in the
company's filings with the Securities and Exchange Commission,
including the risks set forth in the company's quarterly report on
Form 10-Q for the quarter ended June 30, 2015. These
forward-looking statements speak only as of the date
hereof. Genomic Health disclaims any obligation to update
these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype
DX, Recurrence Score, and DCIS Score are trademarks or registered
trademarks of Genomic Health, Inc. All other trademarks
and service marks are the property of their respective
owners.
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genomic-health-to-announce-third-quarter-2015-financial-results-and-host-conference-call-on-tuesday-november-3-2015-300163517.html
SOURCE Genomic Health, Inc.